IOX1 impedes host inflammation in imiquimod-triggered psoriasis

Psoriasis is a chronic autoimmune disease with an unknown etiology and highly limited treatment strategies. The drugs currently used in the treatment of psoriasis are rarely recommended for long-term use owing to the serious side effects. Although different targets have been identified for controlli...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Joo Eun Shin, Su Jin Lee, Amal Gharbi, In Duk Jung, Yeong Min Park
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Psoriasis Autoimmune diseases Inflammation Splenocytes Science (General) Q1-390 Social sciences (General) H1-99
Acceso en línea:	https://doaj.org/article/1d3b67afd8034f4d986d008e72250ff2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1d3b67afd8034f4d986d008e72250ff2
record_format	dspace
spelling	oai:doaj.org-article:1d3b67afd8034f4d986d008e72250ff22021-12-02T05:03:12ZIOX1 impedes host inflammation in imiquimod-triggered psoriasis2405-844010.1016/j.heliyon.2021.e08433https://doaj.org/article/1d3b67afd8034f4d986d008e72250ff22021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2405844021025366https://doaj.org/toc/2405-8440Psoriasis is a chronic autoimmune disease with an unknown etiology and highly limited treatment strategies. The drugs currently used in the treatment of psoriasis are rarely recommended for long-term use owing to the serious side effects. Although different targets have been identified for controlling psoriasis, the role of epigenetic modifications as therapeutic targets is yet to be elucidated. Here, we investigated the therapeutic potential of 8-hydroxyquinoline-5-carboxylic acid (IOX1), a novel drug with a genetic target, in psoriasis. The daily topical administration of IOX1 in a mouse model of imiquimod (IMQ)-induced psoriatic inflammation reduced inflammatory reactions in the skin and lowered the PASI score. Furthermore, intraperitoneally injected IOX1 repressed the inflammatory status induced by IMQ in psoriatic mice by reducing the mRNA levels of pro-inflammatory cytokines, restoring splenocyte populations, and regulating macrophage polarization. Our findings indicate the remedial effects of IOX1 on dermatitis psoriasis and the potential of IOX1 as a therapeutic compound in psoriasis.Joo Eun ShinSu Jin LeeAmal GharbiIn Duk JungYeong Min ParkElsevierarticlePsoriasisAutoimmune diseasesInflammationSplenocytesScience (General)Q1-390Social sciences (General)H1-99ENHeliyon, Vol 7, Iss 11, Pp e08433- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Psoriasis Autoimmune diseases Inflammation Splenocytes Science (General) Q1-390 Social sciences (General) H1-99
spellingShingle	Psoriasis Autoimmune diseases Inflammation Splenocytes Science (General) Q1-390 Social sciences (General) H1-99 Joo Eun Shin Su Jin Lee Amal Gharbi In Duk Jung Yeong Min Park IOX1 impedes host inflammation in imiquimod-triggered psoriasis
description	Psoriasis is a chronic autoimmune disease with an unknown etiology and highly limited treatment strategies. The drugs currently used in the treatment of psoriasis are rarely recommended for long-term use owing to the serious side effects. Although different targets have been identified for controlling psoriasis, the role of epigenetic modifications as therapeutic targets is yet to be elucidated. Here, we investigated the therapeutic potential of 8-hydroxyquinoline-5-carboxylic acid (IOX1), a novel drug with a genetic target, in psoriasis. The daily topical administration of IOX1 in a mouse model of imiquimod (IMQ)-induced psoriatic inflammation reduced inflammatory reactions in the skin and lowered the PASI score. Furthermore, intraperitoneally injected IOX1 repressed the inflammatory status induced by IMQ in psoriatic mice by reducing the mRNA levels of pro-inflammatory cytokines, restoring splenocyte populations, and regulating macrophage polarization. Our findings indicate the remedial effects of IOX1 on dermatitis psoriasis and the potential of IOX1 as a therapeutic compound in psoriasis.
format	article
author	Joo Eun Shin Su Jin Lee Amal Gharbi In Duk Jung Yeong Min Park
author_facet	Joo Eun Shin Su Jin Lee Amal Gharbi In Duk Jung Yeong Min Park
author_sort	Joo Eun Shin
title	IOX1 impedes host inflammation in imiquimod-triggered psoriasis
title_short	IOX1 impedes host inflammation in imiquimod-triggered psoriasis
title_full	IOX1 impedes host inflammation in imiquimod-triggered psoriasis
title_fullStr	IOX1 impedes host inflammation in imiquimod-triggered psoriasis
title_full_unstemmed	IOX1 impedes host inflammation in imiquimod-triggered psoriasis
title_sort	iox1 impedes host inflammation in imiquimod-triggered psoriasis
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/1d3b67afd8034f4d986d008e72250ff2
work_keys_str_mv	AT jooeunshin iox1impedeshostinflammationinimiquimodtriggeredpsoriasis AT sujinlee iox1impedeshostinflammationinimiquimodtriggeredpsoriasis AT amalgharbi iox1impedeshostinflammationinimiquimodtriggeredpsoriasis AT indukjung iox1impedeshostinflammationinimiquimodtriggeredpsoriasis AT yeongminpark iox1impedeshostinflammationinimiquimodtriggeredpsoriasis
_version_	1718400695773691904

IOX1 impedes host inflammation in imiquimod-triggered psoriasis

Ejemplares similares